How to buy Intra-Cellular Therapies stock

Intra-Cellular Therapies, Inc is a biotechnology business based in the US. Intra-Cellular Therapies shares (ITCI) are listed on the NASDAQ and all prices are listed in US Dollars. Intra-Cellular Therapies employs 330 staff and has a trailing 12-month revenue of around USD$3.1 million.

How to buy shares in Intra-Cellular Therapies

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Intra-Cellular Therapies. Find the stock by name or ticker symbol: ITCI. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Intra-Cellular Therapies reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Intra-Cellular Therapies, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Intra-Cellular Therapies. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Intra-Cellular Therapies share price

Use our graph to track the performance of ITCI stocks over time.

Intra-Cellular Therapies shares at a glance

• Key figures

Information last updated 2020-10-20.

52-week range	USD$8.27 - USD$43.56
50-day moving average	USD$25.9766
200-day moving average	USD$21.9889
Wall St. target price	USD$54.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.814

Buy Intra-Cellular Therapies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Intra-Cellular Therapies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Intra-Cellular Therapies, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intra-Cellular Therapies financials

Revenue TTM	USD$3.1 million
Gross profit TTM	USD$-89,064,225
Return on assets TTM	-31.98%
Return on equity TTM	-58.64%
Profit margin	0%
Book value	$5.683
Market capitalisation	USD$2.1 billion

TTM: trailing 12 months

Shorting Intra-Cellular Therapies shares

There are currently 5.9 million Intra-Cellular Therapies shares held short by investors – that's known as Intra-Cellular Therapies's "short interest". This figure is 12.9% down from 6.7 million last month.

There are a few different ways that this level of interest in shorting Intra-Cellular Therapies shares can be evaluated.

Intra-Cellular Therapies's "short interest ratio" (SIR)

Intra-Cellular Therapies's "short interest ratio" (SIR) is the quantity of Intra-Cellular Therapies shares currently shorted divided by the average quantity of Intra-Cellular Therapies shares traded daily (recently around 4.1 million). Intra-Cellular Therapies's SIR currently stands at 1.44. In other words for every 100,000 Intra-Cellular Therapies shares traded daily on the market, roughly 1440 shares are currently held short.

However Intra-Cellular Therapies's short interest can also be evaluated against the total number of Intra-Cellular Therapies shares, or, against the total number of tradable Intra-Cellular Therapies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intra-Cellular Therapies's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Intra-Cellular Therapies shares in existence, roughly 70 shares are currently held short) or 0.0835% of the tradable shares (for every 100,000 tradable Intra-Cellular Therapies shares, roughly 84 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Intra-Cellular Therapies.

Find out more about how you can short Intra-Cellular Therapies stock.

Intra-Cellular Therapies share dividends

We're not expecting Intra-Cellular Therapies to pay a dividend over the next 12 months.

Intra-Cellular Therapies share price volatility

Over the last 12 months, Intra-Cellular Therapies's shares have ranged in value from as little as $8.27 up to $43.56. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intra-Cellular Therapies's is 1.6387. This would suggest that Intra-Cellular Therapies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Intra-Cellular Therapies overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Frequently asked questions

• What percentage of Intra-Cellular Therapies is owned by insiders or institutions?

  Currently 6.066% of Intra-Cellular Therapies shares are held by insiders and 69.587% by institutions.

• How many people work for Intra-Cellular Therapies?

  Latest data suggests 330 work at Intra-Cellular Therapies.

• When does the fiscal year end for Intra-Cellular Therapies?

  Intra-Cellular Therapies's fiscal year ends in December.

• Where is Intra-Cellular Therapies based?

  Intra-Cellular Therapies's address is: 430 East 29th Street, New York, NY, United States, 10016

• What is Intra-Cellular Therapies's ISIN number?

  Intra-Cellular Therapies's international securities identification number is: US46116X1019

• What is Intra-Cellular Therapies's CUSIP number?

  Intra-Cellular Therapies's Committee on Uniform Securities Identification Procedures number is: 46116X101